{"favorite_id": 10040, "calc_type": "", "dosing": false, "full_title_en": "Duval/CIBMTR Score for Acute Myelogenous Leukemia (AML) Survival", "short_title_en": "Duval/CIBMTR Score", "medium_description_en": "<span id=\"docs-internal-guid-b31c1b3f-b490-1063-03ed-94f006599a06\">Predicts overall survival in AML patients with relapsed/refractory disease undergoing myeloablative transplant.</span>", "short_description_en": "AML survival.", "before_use": "", "instructions_en": "<p><span id=\"docs-internal-guid-0cc06959-ce3b-dee0-9f16-93dc0a7ea4c5\">Use in patients with relapsed or refractory active AML for whom hematopoietic stem cell transplant (HSCT) is being considered. Do not use in patients with chronic myelogenous leukemia (CML) in blast crisis.</span></p>", "purpose_en": ["Prognosis"], "disease_en": ["Cancer", "Chemotherapy", "Hematologic Malignancy"], "specialty_en": ["Critical Care", "Family Practice", "Internal Medicine", "Primary Care", "Radiation Oncology"], "chief_complaint_en": ["Fever", "Fatigue", "Weight Loss/Gain"], "system_en": ["Hematologic", "Immunologic", "Oncologic"], "search_abbreviation_en": ["Duval Score", "Hematopoietic stem cell transplant", "Duval survival score", " AML survival", "Acute myelogenous leukemia score"], "slug": "duval-cibmtr-score-acute-myelogenous-leukemia-aml-survival", "seo": {"meta_description_en": "The Duval Score for Acute Myelogenous Leukemia (AML) Survival predicts the transplantation survival of AML for patients in complete remission. ", "keywords_en": "Duval Score, AML survival, remission, leukemia "}, "content": {"how_to_use": {"use_case_en": "<p><span id=\"docs-internal-guid-2963ff9b-ce3c-d653-81f9-20d7601579e9\"></span></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Patients with relapsed or refractory active acute myeloid leukemia AML (i.e., NOT in complete remission), for whom myeloablative hematopoietic stem cell transplant (HSCT) is being considered.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Do not use in patients with chronic myelogenous leukemia (CML) in blast crisis.</p>\n</li>\n</ul>", "pearls_pitfalls_en": "<p><span id=\"docs-internal-guid-4ab30f09-61b6-e209-b2f2-0f6de897be4a\"></span><span id=\"docs-internal-guid-9fc45c8e-ccfa-9540-7f37-a7c420c9fe7c\"></span></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Only busulfan and TBI-based regimens were studied in the derivation; reduced-intensity conditioning (RIC) and fludarabine-based regimens were excluded.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Syngeneic and cord blood transplants were also not included in this analysis.</p>\n</li>\n</ul>", "why_use_en": "<p><span id=\"docs-internal-guid-6b8f2924-ce3d-6920-9522-bf45cf1873b0\">Use when deciding between HSCT and additional treatment for patients with relapsed or refractory active disease. </span></p>"}, "next_steps": {"advice_en": "<p><span id=\"docs-internal-guid-f5e0229f-ce3d-9d4b-fb79-560b29f007a7\">High-risk patients with 3-year overall survival (OS) of 6% should be counseled and preferably referred for relapse-mitigation clinical trials.</span></p>", "management_en": "<p><span id=\"docs-internal-guid-61d84b27-ce3d-e2ab-a5bf-f5a3c9fc3317\">HSCT should be considered in patients with scores &le;2 in the context of other available therapies, given their predicted OS of 15-46%.</span></p>", "critical_actions_en": "<p><span id=\"docs-internal-guid-b20ef54c-ce3e-2572-10c2-6c8fb2b93c64\">Risk should be discussed with the patient.</span></p>"}, "about": {"formula_en": "<p dir=\"ltr\">Addition of the selected points:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"*\" /><col width=\"*\" /><col width=\"*\" /><col width=\"*\" /></colgroup>\n<tbody>\n<tr>\n<td><br />\n<p dir=\"ltr\"><strong>Variable</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>0 Points </strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>1 Point </strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>2 Points </strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Disease group</p>\n</td>\n<td>\n<p dir=\"ltr\">Primary induction failure or duration of first complete remission &gt;6 months</p>\n</td>\n<td>\n<p dir=\"ltr\">Duration of first complete remission &lt;6 months</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Cytogenetics prior to HSCT</p>\n</td>\n<td>\n<p dir=\"ltr\">Good or intermediate</p>\n</td>\n<td>\n<p dir=\"ltr\">Poor</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">HLA match group</p>\n</td>\n<td>\n<p dir=\"ltr\">HLA identical sibling or well matched or partially matched unrelated</p>\n</td>\n<td>\n<p dir=\"ltr\">Mismatched unrelated</p>\n</td>\n<td>\n<p dir=\"ltr\">Related other than HLA identical sibling</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Circulating blasts*</p>\n</td>\n<td>\n<p dir=\"ltr\">Absent</p>\n</td>\n<td>\n<p dir=\"ltr\">Present</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Karnofsky or Lansky&nbsp;scale</p>\n</td>\n<td>\n<p dir=\"ltr\">90-100</p>\n</td>\n<td>\n<p dir=\"ltr\">&lt;90</p>\n</td>\n<td>\n<p dir=\"ltr\">--</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\"><span id=\"docs-internal-guid-774f7d32-f24e-22e1-de60-732b589ac343\"></span></p>\n<p dir=\"ltr\">*At the time of transplant.</p>", "more_info_en": "<p dir=\"ltr\">Interpretation:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"118\" /><col width=\"119\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Duval Score</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>3-year overall survival after transplantation</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">0</p>\n</td>\n<td>\n<p dir=\"ltr\">42%</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">1</p>\n</td>\n<td>\n<p dir=\"ltr\">28%</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">2</p>\n</td>\n<td>\n<p dir=\"ltr\">15%</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">&ge;3</p>\n</td>\n<td>\n<p dir=\"ltr\">6%</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><span id=\"docs-internal-guid-da334acd-28a6-0f0d-4be0-3f2c4baf8618\">From <a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917308/pdf/zlj3730.pdf\" target=\"_blank\">Duval 2010</a>.</span></p>\n<p><span></span></p>\n<p></p>", "evidence_based_medicine_en": "<p dir=\"ltr\">The <a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917308/pdf/zlj3730.pdf\" target=\"_blank\">original study</a> was a retrospective analysis of Center for International Blood and Marrow Transplant Research (CIBMTR) data of 1,673 patients with relapsed or refractory AML from 221 centers. All patients had active disease at the time of transplant. Patient, disease, and HSCT characteristics were examined. Median follow-up was 61 months. Overall survival was examined, given the absence of post-transplant remission in some patients. The variables included in the final score were found to be predictors of overall survival in multivariate analysis. A separate prediction model for acute lymphoblastic leukemia (ALL) was also included.</p>\n<p><span id=\"docs-internal-guid-5211c257-ce3f-60e7-8236-5e431e981b2b\">This score was <a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806246/pdf/leu2013208a.pdf\" target=\"_blank\">validated</a> retrospectively using data from GITMO (Italian Group for Blood and Marrow Transplantation), in Italy including an analysis of patients undergoing RIC or cord blood transplant.</span></p>", "references_list": {"Original/Primary Reference": [{"href": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917308/pdf/zlj3730.pdf ", "text": "Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28(23):3730-8."}], "Other References": [{"href": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2212610/ ", "text": "Armand P, Kim HT, Cutler CS, et al. A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14(1):28-35."}, {"href": "https://jamanetwork.com/journals/jamaoncology/fullarticle/2652906", "text": "Sorror ML, Storer BE, Fathi AT, et al. Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality. JAMA Oncol. 2017;3(12):1675-1682. "}], "Validation": [{"href": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806246/pdf/leu2013208a.pdf", "text": "Todisco E, Ciceri F, Oldani E, et al. The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo. Leukemia. 2013;27(10):2086-91."}], "Clinical Practice Guidelines": [{"href": "", "text": ""}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": [{"name": "Joseph Maakaron, MD"}]}, "creator": [{"name": "Dr. Michel Duval", "creator_info": {"about_en": "<p>Michel Duval, MD, is the medical director of the hematopoietic transplantation and Cell Therapy Program at the Charles-Bruneau Cancer Center, at the Sainte-Justine University Hospital Center in Montreal, Canada. He is also the co-chief of the hemato-oncology department at the Centre Hospitalier Universitaire Sainte-Justine. Dr. Duval\u2019s research focuses primarily on immunotherapy of childhood cancers and cord blood transplant immunology.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-michel-duval.jpg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Duval+M%5BAuthor%5D"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "radio", "label_en": "Disease group", "name": "disease", "options": [{"label": "Primary induction failure or duration of first complete remission >6 months", "value": 0}, {"label": "Duration of first complete remission <6 months", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "radio", "label_en": "Cytogenetics prior to HSCT", "name": "cytogenetics", "options": [{"label": "Good or intermediate ", "value": 0}, {"label": "Poor", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "radio", "label_en": " <abbr title='Human leukocyte antigen'>HLA</abbr> match group", "name": "hla", "options": [{"label": "HLA identical sibling or well matched or partially matched unrelated", "value": 0}, {"label": "Mismatched unrelated", "value": 1}, {"label": "Related other than HLA identical sibling", "value": 2}], "conditionality": "", "show_points": true, "default": 0, "optional": false}, {"type": "toggle", "label_en": "Circulating blasts ", "name": "blasts", "options": [{"label": "Absent", "value": 0}, {"label": "Present", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "tips_en": "At the time of transplant", "optional": false}, {"type": "radio", "label_en": "<calculator id=\"3168\">Karnofsky</calculator> or <calculator id=\"3176\">Lanksy</calculator> scale", "name": "karnofsky", "options": [{"label": "90-100", "value": 0}, {"label": "<90", "value": 1}], "conditionality": "", "show_points": true, "default": 0, "optional": false}], "md5": "ff2f7f3e0969602b649166498e32ee46", "related_calcs": [{"calcId": "10066", "short_title_en": "DIPSS", "slug": "dipss-dynamic-international-prognostic-scoring-system-myelofibrosis"}, {"calcId": "4054", "short_title_en": "CLL-IPI", "slug": "international-prognostic-index-chronic-lymphocytic-leukemia-cll-ipi"}, {"calcId": "3980", "short_title_en": "HCT-CI", "slug": "hematopoietic-cell-transplantation-specific-comorbidity-index-hct-ci"}]}